TABLE 1.
Genes That Interfere With GBC-Specific Sensitivity to Chemotherapeutics
| Gene symbol | Cell lines | Drugs | Research types | Event | Sensitivity to drugs (in vitro) | Tumor volume vs. control (in vivo) | Sample size; median survival time (mo) |
|---|---|---|---|---|---|---|---|
| CRT | GBC-SD+NOZ | GEM17 | vtr+cli | KD OE | Up Down | — — | 7; 28 25; 16 |
| LncRNA-RP11-147L13.8 | GBC-SD+NOZ | GEM18 | vtr+cli | KD OE | Down Up | — — | 48; 30 48; 50 |
| Lnc-RNA-MYLK-AS1 | GBC-SD+NOZ+EH-GB1+SGC-996 | GEM19 | vtr+cli | KD OE | Up Down | — — | 60; 60 60; 20 |
| Lnc-RNA-SSTR5-AS1 | GBC-SD+NOZ | GEM20 | vvo+vtr+cli | KD OE | Up Down | Smaller — | 54; 50 56; >80 |
| MiR-205-5p | GBC-SD | GEM21 | vvo+vtr+cli | KD OE | Down Up | — Smaller | 68; 25 68; 40 |
| ELP5 | GBC-SD+NOZ | GEM22 | vvo+vtr+cli | KO OE | Down Up | Bigger — | 10; 60 50; 22 |
| MBD1 | GBC-SD+SGC-996 | GEM23 | vtr+cli | KD — | Up — | — — | 26; 25 58; 15 |
| MiR-218-5p | GBC-SD+NOZ | GEM24 | vvo+vtr+cli | KD OE | Down Up | — Smaller | 42; 10 40; 20 |
| MiR-125b-5p | NOZ+GBC-SD+SGC-996 | CDDP25 | vvo+vtr+cli | KD OE | Down Up | — Smaller | 41; 10 41; 20 |
| aPKCι | GBC-SD+NOZ | GEM26 | vvo+vtr+cli | KD — | Up — | Smaller — | 23; 50 49; 5 |
| MiR-433 | GBC-SD | GEM27 | vtr | — OE | — Down | — — | — — |
| GLI2 | TYGBK-1+NOZ+TGBC2TKB | GEM28 | vvo+vtr+cli | KD — | Down — | Smaller — | 9; 50 5; >60 |
| UCP2 | G-415 | GEM29 | vvo+vtr+cli | KD — | Up — | — — | — — |
| NOX1 | GBC-SD+SGC-996 | CDDP30 | vvo+vtr | KD OE | Up Down | Smaller — | — — |
| FXR | SGC-996+QGC939+GBC-SD | CDDP31 | vvo+vtr+cli | — Activate | — Up | — Smaller | — — |
| MiR-1207-5p | GBC-SD | CDDP32 | vtr | Inhibit Activate | Up Down | — — | — — |
| V-SRC | HAG-1 | CDDP33 | vtr | — OE | — Down | — — | — — |
| MiR-31 | GBC-SD+NOZ | CDDP34 | vvo+vtr | — OE | — Up | — Smaller | — — |
| C-ERBB-2 | HAG-2 | CDDP35 | vtr | — OE | — Up | — — | — — |
| OLFM4 | GBC-SD | CDDP36 | vvo+vtr+cli | KD — | Up — | Smaller — | 10; 20 30; 10 |
| GBCDRlnc1 | GBC-SD+NOZ | DOX+5-FU37 | vvo+vtr+cli | KD OE | Up Down | Smaller — | 22; 15 23; 8 |
| MiR-1231 | GBC-SD+NOZ | DTX38 | vtr+cli | — OE | — Up | — — | — — |
| MiR-335 | GBC-SD+SGC-996 | 5-FU39 | vtr | — OE | — Up | — — | — — |
| XRCC1 | GBC-SD | 5-FU40 | vtr+cli | KD — | Up — | — — | 86; 13 129; 9 |
| PLAC8 | SGC-996GR+SGC-996OR | GEM+OXA41 | vtr | KD — | Up — | — — | — — |
| DUSP1 | SGC996+GBC-SD | CDDP+5-FU42 | vtr | — OE | — Down | — — | — — |
5-FU indicates 5-fluorouracil; CDDP, cisplatin; cli, clinical research; Dox, doxorubicin; DTX, docetaxel; GBC, gallbladder cancer; GEM, gemcitabine; KD, knockdown; KO, knockout; OE, overexpress; OXA, oxaliplatin; vtr, in vitro; vvo, in vivo.